Skip to main content
    K

    Kestra Medical Technologies, Ltd. Common Stock (KMTS)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $27.97
    -0.67 (-2.34%)

    Market Cap: $1.71B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Kestra Medical Technologies, Ltd. Common Stock (KMTS) Financials: Revenue, Profit and Cash Flow

    Updated Sep 14, 2026. Financial statements from company filings, amounts in US dollars.

    Kestra Medical Technologies, Ltd. Common Stock reported revenue of $95.13M for the fiscal year ended Apr 30, 2026, up 59.0% from the year before. That year, net income was -$131.61M with a net margin of -138.4%, operating cash flow was -$81.70M and free cash flow was -$116.59M. The quarter ended Jul 31, 2026 had revenue of $30.97M and net income of -$44.09M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Apr 2026$95.13M+59.0%51.4%-141.6%-138.4%
    Apr 2025$59.81M+115.1%40.5%-177.8%-190.3%
    Apr 2024$27.81M+264.5%1.3%-305.8%-338.4%
    Apr 2023$7.63MN/A-139.6%-1054.0%-1104.0%
    Apr 2021$0N/AN/AN/AN/A
    Apr 2020$0N/AN/AN/AN/A
    Annual, fiscal years ended Apr 2020 to Apr 2026

    Income Statement

    In the fiscal year ended Apr 2026, the net loss widened from the year before. In the quarter ended Jul 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2021Apr 2020
    Revenue$95.13M$59.81M$27.81M$7.63M$0$0
    Cost of revenue$46.26M$35.60M$27.45M$18.28MN/AN/A
    Gross profit$48.86M$24.21M$362.00K-$10.65MN/AN/A
    Research and development$19.48M$15.65M$15.49M$15.76M$18.81M$22.80M
    Operating income-$134.74M-$106.38M-$85.06M-$80.42M-$32.71M-$29.32M
    Net income-$131.61M-$113.81M-$94.12M-$84.24M-$34.10M-$29.47M
    EBITDA-$121.65M-$99.78M-$75.70M-$73.74M-$32.33M-$28.84M
    Fiscal years ended Apr 2020 to Apr 2026

    Quarterly

    Line itemJul 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023Jul 2023
    Revenue$30.97M$24.55M$22.57M$19.37M$2.79M$15.09M$14.71M$12.78M$10.05M$8.28M$14.71M$12.78M
    Gross profit$17.50M$12.91M$11.42M$8.85M-$2.61M$6.55M$5.83M$4.20M$1.40M$880.00K$5.83M$4.20M
    Operating income-$37.66M-$34.77M-$31.75M-$28.88M-$25.14M-$20.60M-$19.13M-$18.43M-$20.35M-$19.95M-$19.13M-$18.43M
    Net income-$44.09M-$34.17M-$32.78M-$25.83M-$33.69M-$21.51M-$20.37M-$19.88M-$22.28M-$21.62M-$20.37M-$19.88M
    Last 12 quarters

    Balance Sheet

    As of Apr 2026, cash and equivalents exceeded long-term debt of $42.65M by $57.06M.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2021Apr 2020
    Total assets$358.46M$295.74M$45.95M$38.66M$30.52M$7.87M
    Current assets$222.36M$255.33M$14.91M$18.42M$26.20M$6.17M
    Cash and equivalents$99.71M$237.59M$8.25M$14.81M$24.34M$5.76M
    Total liabilities$98.81M$90.34M$78.22M$156.23M$28.76M$4.02M
    Short-term debtN/A$374.00KN/A$21.81M$1.06M$452.00K
    Long-term debt$42.65M$41.10M$42.54M$17.32M$20.24MN/A
    Shareholder equity$259.66M$205.41M$0-$117.58M$1.77M$3.86M
    Fiscal years ended Apr 2020 to Apr 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Apr 2023
    Total assets$347.36M$358.46M$379.34M$246.70M$266.30M$295.74M$108.00M$246.70M$266.30M$45.95MN/A$38.66M
    Total liabilities$125.00M$98.81M$91.35M$82.62M$82.14M$90.34M$85.38M$82.62M$82.14M$255.33MN/A$156.23M
    Cash and equivalents$68.56M$99.71M$291.32M$175.42M$201.21M$237.59M$54.35M$175.42M$201.21M$8.25MN/A$14.81M
    Shareholder equity$222.36M$259.66M$287.99M$164.08M$184.16M$205.41M-$274.05M$164.08M$184.16M-$209.38MN/A-$117.58M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Apr 2026.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2021Apr 2020
    Operating cash flow-$81.70M-$77.61M-$72.23M-$69.64M-$29.89M-$30.29M
    Capital expenditures$34.89M$22.94M$12.23M$15.46M$336.00K$232.00K
    Free cash flow-$116.59M-$100.54M-$84.46M-$85.10M-$30.23M-$30.52M
    Dividends paidN/A$1.65M$799.00K$671.00K$187.00K$183.00K
    Share repurchases$2.47M$3.22M$0N/AN/AN/A
    Investing cash flow-$203.28M-$23.31M-$12.23M-$15.46M-$334.00K-$232.00K
    Financing cash flow$147.09M$330.26M$77.72M$96.11M$48.81M$30.24M
    Fiscal years ended Apr 2020 to Apr 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Operating cash flow-$32.30M-$18.72M-$18.37M-$18.34M-$26.27M-$24.06M-$8.94M-$18.06M-$17.50M-$14.95M-$15.80M-$18.06M
    Capital expenditures$8.34M$9.66M$9.80M$7.26M$8.17M$7.39M$116.00K$4.45M$7.04M$4.11M$4.97M$4.45M
    Free cash flow-$40.63M-$28.38M-$28.16M-$25.61M-$34.44M-$31.45M-$9.05M-$22.50M-$24.54M-$19.06M-$20.76M-$22.50M
    Last 12 quarters

    Frequently Asked Questions About KMTS

    What is Kestra Medical Technologies, Ltd. Common Stock's annual revenue?

    Kestra Medical Technologies, Ltd. Common Stock reported revenue of $95.13M for the fiscal year ended Apr 30, 2026.

    How fast is Kestra Medical Technologies, Ltd. Common Stock's revenue growing?

    Revenue was up 59.0% for the fiscal year ended Apr 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 131.9%.

    Is Kestra Medical Technologies, Ltd. Common Stock profitable?

    No. Kestra Medical Technologies, Ltd. Common Stock reported net income of -$131.61M for the fiscal year ended Apr 30, 2026, with a net margin of -138.4%.

    How much free cash flow does KMTS generate?

    For the fiscal year ended Apr 30, 2026, operating cash flow of -$81.70M minus capital expenditures of $34.89M produced free cash flow of -$116.59M.

    How much debt does Kestra Medical Technologies, Ltd. Common Stock have?

    The balance sheet dated Apr 30, 2026 reported long-term debt of $42.65M and cash and equivalents of $99.71M.